Characterizing uncertainty and variability in physiologically based pharmacokinetic models: state of the science and needs for research and implementation.

Physiologically based pharmacokinetic (PBPK) models are used in mode-of-action based risk and safety assessments to estimate internal dosimetry in animals and humans. When used in risk assessment, these models can provide a basis for extrapolating between species, doses, and exposure routes or for justifying nondefault values for uncertainty factors. Characterization of uncertainty and variability is increasingly recognized as important for risk assessment; this represents a continuing challenge for both PBPK modelers and users. Current practices show significant progress in specifying deterministic biological models and nondeterministic (often statistical) models, estimating parameters using diverse data sets from multiple sources, using them to make predictions, and characterizing uncertainty and variability of model parameters and predictions. The International Workshop on Uncertainty and Variability in PBPK Models, held 31 Oct-2 Nov 2006, identified the state-of-the-science, needed changes in practice and implementation, and research priorities. For the short term, these include (1) multidisciplinary teams to integrate deterministic and nondeterministic/statistical models; (2) broader use of sensitivity analyses, including for structural and global (rather than local) parameter changes; and (3) enhanced transparency and reproducibility through improved documentation of model structure(s), parameter values, sensitivity and other analyses, and supporting, discrepant, or excluded data. Longer-term needs include (1) theoretical and practical methodological improvements for nondeterministic/statistical modeling; (2) better methods for evaluating alternative model structures; (3) peer-reviewed databases of parameters and covariates, and their distributions; (4) expanded coverage of PBPK models across chemicals with different properties; and (5) training and reference materials, such as cases studies, bibliographies/glossaries, model repositories, and enhanced software. The multidisciplinary dialogue initiated by this Workshop will foster the collaboration, research, data collection, and training necessary to make characterizing uncertainty and variability a standard practice in PBPK modeling and risk assessment.

[1]  Stefano Tarantola,et al.  Sensitivity Analysis as an Ingredient of Modeling , 2000 .

[2]  R C Spear,et al.  Mechanisms of benzene carcinogenesis: application of a physiological model of benzene pharmacokinetics and metabolism. , 1991, Toxicology letters.

[3]  F. A. Smith,et al.  Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. , 1987, Toxicology and applied pharmacology.

[4]  Harvey J Clewell,et al.  Evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry. , 2004, Toxicological sciences : an official journal of the Society of Toxicology.

[5]  Melvin E. Andersen,et al.  Gas Uptake Inhalation Techniques and the Rates of Metabolism of Chloromethanes, Chloroethanes, and Chloroethylenes in the Rat , 1990 .

[6]  W Thormann,et al.  Antinociceptive effects, metabolism and disposition of ketamine in ponies under target-controlled drug infusion. , 2006, Toxicology and applied pharmacology.

[7]  Malcolm Rowland,et al.  Lumping of Whole-Body Physiologically Based Pharmacokinetic Models , 1998, Journal of Pharmacokinetics and Biopharmaceutics.

[8]  Richard D. Thomas Drinking Water and Health , 1986 .

[9]  Frédéric Y. Bois,et al.  Assessing the reliability of PBPK models using data from methyl chloride-exposed, non-conjugating human subjects , 2001, Archives of Toxicology.

[10]  N. Singpurwalla,et al.  Membership Functions and Probability Measures of Fuzzy Sets , 2004 .

[11]  Michael A. Gallo,et al.  Reconstruction of short-term multi-route exposure to volatile organic compounds using physiologically based pharmacokinetic models , 1994 .

[12]  K. Bischoff,et al.  Methotrexate pharmacokinetics. , 1971, Journal of pharmaceutical sciences.

[13]  Joseph G. Ibrahim,et al.  A Bayesian compartmental model for the evaluation of 1,3‐butadiene metabolism , 2003 .

[14]  G. Casella,et al.  Statistical Inference , 2003, Encyclopedia of Social Network Analysis and Mining.

[15]  Thomas J. Smith,et al.  Development of a physiologically based toxicokinetic model for butadiene and four major metabolites in humans: global sensitivity analysis for experimental design issues. , 2007, Chemico-biological interactions.

[16]  R. Coulombe,et al.  Pharmacokinetics in Risk Assessment , 1996 .

[17]  M C Kohn,et al.  A physiologically based pharmacokinetic model for inhalation and intravenous administration of naphthalene in rats and mice. , 2001, Toxicology and applied pharmacology.

[18]  Walter Schmitt,et al.  Development and Evaluation of a Generic Physiologically Based Pharmacokinetic Model for Children , 2006, Clinical pharmacokinetics.

[19]  Malcolm Rowland,et al.  Fuzzy Simulation of Pharmacokinetic Models: Case Study of Whole Body Physiologically Based Model of Diazepam , 2004, Journal of Pharmacokinetics and Pharmacodynamics.

[20]  Walter Schmitt,et al.  Development of a Physiology-Based Whole-Body Population Model for Assessing the Influence of Individual Variability on the Pharmacokinetics of Drugs , 2007, Journal of Pharmacokinetics and Pharmacodynamics.

[21]  A Gelman,et al.  Optimal design for a study of butadiene toxicokinetics in humans. , 1999, Toxicological sciences : an official journal of the Society of Toxicology.

[22]  R H Reitz,et al.  Non-linear pharmacokinetic parameters need to be considered in high dose/low dose extrapolation. , 1980, Archives of toxicology. Supplement. = Archiv fur Toxikologie. Supplement.

[23]  Gunnar Johanson,et al.  A human physiological model describing acetone kinetics in blood and breath during various levels of physical exercise. , 2006, Toxicology letters.

[24]  J. C. Helton,et al.  An Investigation of Uncertainty and Sensitivity Analysis Techniques for Computer Models , 1988 .

[25]  James J. Buckley Decision Making Under Risk: A Comparison of Bayesian and Fuzzy Set Methods , 1983 .

[26]  Fredrik U. Jönsson,et al.  Physiologically based pharmacokinetic modeling of inhalation exposure of humans to dichloromethane during moderate to heavy exercise. , 2001, Toxicological sciences : an official journal of the Society of Toxicology.

[27]  H J Clewell,et al.  Incorporation of pharmacokinetics in noncancer risk assessment: example with chloropentafluorobenzene. , 1994, Risk analysis : an official publication of the Society for Risk Analysis.

[28]  G. Johanson,et al.  Spreadsheet programming--a new approach in physiologically based modeling of solvent toxicokinetics. , 1988, Toxicology letters.

[29]  J. G. Kalbfleisch Probability and Statistical Inference , 1977 .

[30]  C DeRosa,et al.  Using structural information to create physiologically based pharmacokinetic models for all polychlorinated biphenyls. , 1997, Toxicology and applied pharmacology.

[31]  A. Gelman,et al.  Physiological Pharmacokinetic Analysis Using Population Modeling and Informative Prior Distributions , 1996 .

[32]  P. Müller Simulation Based Optimal Design , 2005 .

[33]  A. Saltelli,et al.  Sensitivity Anaysis as an Ingredient of Modeling , 2000 .

[34]  Aldo Rescigno,et al.  The use and abuse of models , 1987, Journal of Pharmacokinetics and Biopharmaceutics.

[35]  H. B. Matthews,et al.  Using Structural Information to Create Physiologically Based Pharmacokinetic Models for All Polychlorinated Biphenyls: I. Tissue:Blood Partition Coefficients , 1997 .

[36]  H J Clewell,et al.  Applying simulation modeling to problems in toxicology and risk assessment--a short perspective. , 1995, Toxicology and applied pharmacology.

[37]  Hugh A Barton,et al.  Framework for Evaluation of Physiologically‐Based Pharmacokinetic Models for Use in Safety or Risk Assessment , 2004, Risk analysis : an official publication of the Society for Risk Analysis.

[38]  P. J. Green,et al.  Probability and Statistical Inference , 1978 .

[39]  D J Paustenbach,et al.  A physiological pharmacokinetic description of the tissue distribution and enzyme-inducing properties of 2,3,7,8-tetrachlorodibenzo-p-dioxin in the rat. , 1990, Toxicology and applied pharmacology.

[40]  L. Stark,et al.  Three algorithms for interpreting models consisting of ordinary differential equations: Sensitivity coefficients, sensitivity functions, global optimization , 1982 .

[41]  Malcolm Rowland,et al.  Reducing Whole Body Physiologically Based Pharmacokinetic Models Using Global Sensitivity Analysis: Diazepam Case Study , 2006, Journal of Pharmacokinetics and Pharmacodynamics.

[42]  M C Kohn,et al.  Effects of the structure of a toxicokinetic model of butadiene inhalation exposure on computed production of carcinogenic intermediates. , 1996, Toxicology.

[43]  M E Andersen,et al.  Physiological modeling reveals novel pharmacokinetic behavior for inhaled octamethylcyclotetrasiloxane in rats. , 2001, Toxicological sciences : an official journal of the Society of Toxicology.